Olanzapine

Phase 3Completed

0 watching 0 views this week📈 Rising

Hype Score

Development Stage

✓

Pre-clinical

✓

Phase 1

✓

Phase 2

Phase 3

Approved

Indication / Disease

Borderline Personality Disorder

Conditions

Borderline Personality Disorder

Trial Timeline

Feb 1, 2004 → Jan 1, 2006

NCT ID

NCT00088036

About Olanzapine

Olanzapine is a phase 3 stage product being developed by Eli Lilly for Borderline Personality Disorder. The current trial status is completed. This product is registered under clinical trial identifier NCT00088036. Target conditions include Borderline Personality Disorder.

Hype Score Breakdown

Clinical

Activity

Company

Novelty

Community

Clinical Trials (16)

NCT ID	Phase	Status	Start	Completion	Indication
NCT00982020	Approved	Completed	Sep 1, 2009	May 1, 2013	Bipolar I Disorder
NCT00618748	Phase 3	Completed	Feb 1, 2008	Sep 1, 2010	Bipolar I Disorder
NCT00568672	Phase 3	Withdrawn	Oct 1, 2007	Apr 1, 2008	Relapse Rate of a Major Depressive Episode
NCT00510211	Pre-clinical	Completed	Apr 1, 2007	May 1, 2009	Schizophrenia
NCT00290121	Approved	Completed	Sep 1, 2006	Jun 1, 2008	Schizophrenia
NCT00275301	Pre-clinical	Completed	Dec 1, 2005	Dec 1, 2008	Borderline Personality Disorder
NCT00259272	Phase 3	Completed	Nov 1, 2005	May 1, 2008	Bipolar Disorder I or II
NCT00113594	Phase 3	Completed	Jun 1, 2005	Mar 1, 2006	Schizophrenia
NCT00191997	Approved	Completed	Oct 1, 2004	Mar 1, 2006	Bipolar Disorder
NCT00088036	Phase 3	Completed	Feb 1, 2004	Jan 1, 2006	Borderline Personality Disorder
NCT00100776	Approved	Completed	Sep 1, 2003	Nov 1, 2005	Schizophrenia
NCT00191828	Approved	Completed	Mar 1, 2003	Aug 1, 2005	Weight Gain
NCT00194064	Phase 3	Terminated	Jul 1, 2002	Feb 1, 2006	Bipolar Disorder
NCT00036088	Approved	Completed	Aug 1, 2001	Jul 1, 2002	Schizophrenia
NCT00260962	Phase 2	Completed	Sep 1, 2000	Sep 1, 2006	Anorexia Nervosa
NCT00182507	Approved	Completed	Jun 1, 2000	Mar 1, 2006	Trichotillomania

Competing Products

12 competing products in Borderline Personality Disorder

See all competitors

Product	Company	Stage	Hype Score
Olanzapine + placebo	Eli Lilly	Phase 3	77
olanzapine	Eli Lilly	Pre-clinical	23
Liposomal Irinotecan, Oxaliplatin, 5-Fluorouracil/Calcium folinate in combination with Camrelizumab + Liposomal Irinotecan, Oxaliplatin, 5-Fluorouracil/Calcium folinate	Jiangsu Hengrui Medicine	Phase 2	52
Durvalumab + Tremelimumab + Gemcitabine + Cisplatin	AstraZeneca	Phase 2	52
quetiapine extended-release + Placebo	AstraZeneca	Phase 3	77
Quetiapine fumarate + Placebo	AstraZeneca	Phase 2	52
Quetiapine Fumarate	AstraZeneca	Phase 3	77
ziprasidone + Placebo	Pfizer	Phase 2	51
Fluorouracil + Irinotecan + Irinotecan Hydrochloride + Leucovorin + Leucovorin Calcium + Nivolumab + Oxaliplatin	Bristol Myers Squibb	Phase 1	32
PD-1/PD-L1 inhibitors + Chemotherapy	BeOne Medicines	Phase 2	49
Fluorouracil + Irinotecan + Leucovorin + Leucovorin Calcium + Oxaliplatin + Quemliclustat + Zimberelimab	Arcus Biosciences	Phase 1/2	36
vafidemstat + Placebo	Oryzon Genomics	Phase 2	44

Other Products from Eli Lilly

Insulin Glargine + Insulin Lispro Premix (mid-mixture and low-mixture)Approved

Olanzapine + PlaceboApproved

exenatide and sitagliptin + exenatide and placeboApproved

Tirzepatide + PlaceboApproved

tadalafilApproved